Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Equity (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Return on Equity for 13 consecutive years, with 0.48% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 5.0% year-over-year to 0.48%, compared with a TTM value of 0.48% through Dec 2025, down 5.0%, and an annual FY2025 reading of 0.02%, up 2.0% over the prior year.
  • Return on Equity was 0.48% for Q4 2025 at Karyopharm Therapeutics, down from 0.57% in the prior quarter.
  • Across five years, Return on Equity topped out at 5.11% in Q1 2023 and bottomed at 30.01% in Q1 2021.
  • Average Return on Equity over 5 years is 0.2%, with a median of 1.0% recorded in 2022.
  • The sharpest move saw Return on Equity plummeted -2829bps in 2021, then skyrocketed 3134bps in 2022.
  • Year by year, Return on Equity stood at 1.21% in 2021, then skyrocketed by 75bps to 2.11% in 2022, then tumbled by -42bps to 1.21% in 2023, then tumbled by -57bps to 0.52% in 2024, then dropped by -9bps to 0.48% in 2025.
  • Business Quant data shows Return on Equity for KPTI at 0.48% in Q4 2025, 0.57% in Q3 2025, and 0.7% in Q2 2025.